Drug intelligence / Profile preview

ZK2502

Development stage: Preclinical
Lead developer: Lee's Pharmaceutical
Modality: Small Molecules

Overview

ZK2502 is a preclinical-stage oncology candidate being developed by Lee's Pharmaceutical for the treatment of solid tumors. The drug is currently in the early stages of research and development, and its specific molecular target and mechanism of action have not been publicly disclosed by the sponsor. It is part of Lee's Pharmaceutical's oncology pipeline, which focuses on addressing various malignancies through both internal discovery and strategic partnerships.

Other names: ZK2502ZK-2502ZK 2502

Beyond the preview

Go deeper on ZK2502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZK2502.

Explore the full profile